MEDP

Medpace Holdings, Inc.

Fundamental data last updated:August 26, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Diagnostics & Research

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

 


Analyze MEDP on TradingView

VALUATION

P/E

27.97

Market Cap ($M USD)

$12.93B

Forward P/E

18.50

PEG

0.36

PRICE TO SALES

4.83

PRICE TO BOOK

21.52

EV / EBITDA

21.42

5-Year Average P/E

Free Cash Flow Yield

5.71%

DCF Value

$430.48

Graham Number

$87.52

Price to FCF

17.52

EV to FCF

16.84

Earnings Yield

3.58%

FCF Yield

5.71%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$16.19

Next Year EPS Growth Estimate

$24.47

Next Year Revenue Growth Estimate

$3.73B

Return on Equity (ROE)

120.89%

FREE CASH FLOW

Operating Margin

21.02%

Debt-to-Equity

0.55

Piotroski F-Score

7

Altman Z-Score

6.81

Return on Invested Capital (ROIC)

71.75%

Current Ratio

0.85

Quick Ratio

0.85

Net Debt to EBITDA

-0.87

Interest Coverage

0.00

Gross Profit margin

29.07%

FCF PER SHARE

$25.94

REVENUE PER SHARE

$94.16

Analyze MEDP on TradingView

Gainseekers Quantitative Analysis

Summary

MEDP’s valuation presents a compelling narrative of potential mispricing. Recent pricing indicated it traded below its DCF value, suggesting an undervaluation opportunity. The Forward P/E of 17.33 is attractive, especially when paired with a robust Earnings Yield of 3.82%, indicating solid earnings potential relative to price. The Altman Z-score of 6.54 underscores its financial stability, reducing bankruptcy risk. However, the Price/Book ratio of 20.16 raises questions about market expectations and potential overvaluation.

AI Exposure / Tech Reliance

Operating within the Medical - Diagnostics & Research industry, MEDP is strategically positioned to leverage AI advancements. The sector's reliance on data analytics and precision diagnostics aligns well with AI integration, enhancing operational efficiencies. This adaptability ensures MEDP remains resilient amidst technological shifts.

The Bull Case

For the discerning GARP investor, MEDP offers a tantalizing proposition. With an impressive ROIC of 71.75%, the company demonstrates exceptional capital efficiency, translating into superior returns. A Piotroski F-Score of 7 signals strong financial health, while a Free Cash Flow Yield of 6.09% highlights its ability to generate cash effectively. The operating margin of 21.02% further underscores its pricing power and operational prowess.

The Bear Case

Despite its strengths, MEDP is not without vulnerabilities. The Price/Sales ratio of 4.52 and Price/Book of 20.16 suggest a premium valuation that could deter value investors. Additionally, the stock's proximity to its 52-week high, with a 48.33% distance, indicates potential technical overextension. The low Current and Quick Ratios of 0.85 also point to liquidity concerns that could impact short-term financial flexibility.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$498.86

Institutional Ownership %

1-Year Beta

1.19

Insider Buying % (6 Mo)

Distance to 52-Week High

38.93%

Distance to 52-Week Low

35.66%

EARNINGS SURPRISE %

14.44%

50-DAY SMA

$455.69

200-DAY SMA

$512.94

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.